30.01.2013 Views

Encyclopedia of Drugs, Alcohol, and Addictive Behavior (vol

Encyclopedia of Drugs, Alcohol, and Addictive Behavior (vol

Encyclopedia of Drugs, Alcohol, and Addictive Behavior (vol

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Vol. 3: pp. 947–1372; Vol. 4: pp. 1373–1864 INDEX<br />

DES. See Diethylstilbestrol<br />

Designer drugs, 383–385, 384, 589–590<br />

Controlled Substances Act <strong>of</strong> 1970 <strong>and</strong>,<br />

352<br />

MPTP <strong>and</strong>, 746<br />

WHO <strong>and</strong>, 1366<br />

Desipramine, 135–136<br />

alcohol pharmacotherapy <strong>and</strong>, 1155–1156<br />

for cocaine addiction, 1254–1255<br />

polydrug addiction <strong>and</strong>, 1170–1171,<br />

1196<br />

withdrawal symptoms, 1159, 1170<br />

Desmethyldiazepam, 172<br />

Desoxyn. See Methamphetamines<br />

Desperation phase <strong>of</strong> gambling, 563<br />

DET. See Dimethyltryptamine<br />

Deterrence<br />

for drunk driving, 472<br />

for tobacco addiction, 1205<br />

Detoxification, 385, 1216. See also<br />

Withdrawal<br />

from alcohol, 73–74<br />

from cocaine, 1158–1159<br />

from heroin, 1182<br />

myths about, 748<br />

naltrexone <strong>and</strong>, 752–753, 970<br />

nonmedical, 1246–1249<br />

from opioids, 804–805<br />

pharmacotherapy for, 1219<br />

from polydrug addiction, 1195–1196<br />

Detroit, Michigan <strong>and</strong> gangs, 567, 568,<br />

571–572<br />

Dews, Peter, 1003<br />

Dexamethasone, 705<br />

Dexfenfluramine, 902<br />

Dextroamphetamine, 111–112, 385, 722<br />

Diabetes, elderly, alcohol <strong>and</strong>, 61<br />

Diacetylmorphine. See Heroin<br />

3, 6-diacetylmorphine. See Heroin<br />

Diagnosis <strong>of</strong> substance abuse, 385–393<br />

abuse vs. harmful use, 389<br />

alcoholism, 1143<br />

DAST, 147, 147–148<br />

dependence syndrome criteria, 390<br />

family therapy <strong>and</strong>, 1234<br />

gambling addiction, 551–555<br />

heroin, 1174<br />

HIV Risk Assessment Battery, 148–150<br />

polydrug addiction, 1190<br />

T-ACE screening test, 150–151, 151<br />

withdrawal symptoms (See Withdrawal)<br />

Diagnostic <strong>and</strong> Statistical Manual <strong>of</strong> Mental<br />

Disorders-IV, 393–395<br />

abuse vs. harmful use, 388, 389<br />

on ADHD, 154–155<br />

on alcohol disorders, 102–103, 399<br />

on antisocial personality disorder,<br />

137–138<br />

on conduct disorder, 346–347<br />

on craving, 356<br />

on dependence syndrome, 23–24,<br />

314–315, 383, 388–393, 401, 402,<br />

disease10t<br />

criteria for, 390<br />

withdrawal symptoms, 392<br />

DIS <strong>and</strong>, 395, 396–397<br />

on gambling, 551–552, 553, 560<br />

on nicotine withdrawal, 1348–1349<br />

on personality disorders, 843–844<br />

on polydrug addiction, 1194<br />

purposes <strong>of</strong>, 386<br />

on schizophrenia, 1015–1016<br />

structured clinical interview for (See<br />

Structured clinical interview for<br />

DSM-IV)<br />

substance abuse definition, 176<br />

Diagnostic Criteria for Research (ICD), 655<br />

Diagnostic Interview Schedule, 154, 387,<br />

395–397<br />

Diamonds (Gang), 571, 572–574<br />

Diamorphine. See Heroin<br />

Dianova. See Le Patriarche<br />

Diazepam, 173. See also Benzodiazepines<br />

abuse liability <strong>of</strong>, 176–177<br />

for alcoholism, 1251–1252<br />

for anxiety, 178<br />

for barbiturate withdrawal, 163<br />

behavioral economics <strong>and</strong>, 168<br />

interactions with alcohol, 435<br />

metabolism <strong>of</strong>, 172<br />

methadone with, 177<br />

for neonatal withdrawal symptoms, 17<br />

for status epilepticus, 174–175<br />

WHO <strong>and</strong>, 1366–1367<br />

withdrawal symptoms, 180–181<br />

Didanosine, 1061<br />

Diet pills. See Anorectic agents<br />

Diethylstilbestrol, 220<br />

Digestive cancers <strong>and</strong> alcohol, 219–220, 306<br />

Digoxin <strong>and</strong> immunoassays, 627, 628–629<br />

Dihydromorphine, 397, 397<br />

Dihydroxyphenylacetic acid. See Dopa<br />

3, 4-dihydroxyphenylethylamine. See<br />

Dopamine<br />

Dilaudid. See Hydromorphone<br />

Dimethyltryptamine, 397–398, 398, 589,<br />

1024<br />

3, 7-dimethylxanthine. See Theobromine<br />

Dionysus (Greek deity), 77–79<br />

Diphenhydramine, 1021<br />

Direct-to-consumer drug advertising, 43–44<br />

DIS. See Diagnostic Interview Schedule<br />

Disability programs, Social Security,<br />

483–485<br />

Discontinuance syndrome. See Withdrawal<br />

Discrimination (Drug)<br />

abuse liability testing <strong>and</strong>, 3, 6<br />

animal research on, 988–989, 992–993<br />

conditioning <strong>and</strong>, 971–974<br />

dose-response relationship, 973<br />

phencyclidine <strong>and</strong>, 863<br />

DISCUS, 41, 408–410<br />

The Disease Concept <strong>of</strong> <strong>Alcohol</strong>ism, 1124<br />

Disease concept <strong>of</strong> substance abuse,<br />

398–405<br />

AA <strong>and</strong>, 90, 1214, 1266–1267<br />

CA <strong>and</strong>, 1162–1163<br />

criteria for, 400<br />

defined, 400<br />

gambling <strong>and</strong>, 560–561<br />

history <strong>of</strong> treatment <strong>and</strong>, 1123–1125<br />

inebriate asylums <strong>and</strong>, 1118–1120<br />

Minnesota Model <strong>and</strong>, 1244, 1245<br />

myths about, 748–749<br />

NA <strong>and</strong>, 757<br />

NCADD <strong>and</strong>, 759<br />

treatment methods <strong>and</strong>, 1190–1191<br />

Dispositional tolerance, 25<br />

Disruptive behavior disorder. See Attention<br />

deficit/hyperactivity disorder<br />

Dissociative anesthetics. See Ketamine;<br />

Phencyclidine<br />

Distillation, 405–406<br />

moonshine <strong>and</strong>, 741<br />

stills for, 1055<br />

Distilled spirits, 40–41, 406–408, 407, 408<br />

Distilled Spirits Council <strong>of</strong> the United States,<br />

Inc., 41, 408–410<br />

Distribution <strong>of</strong> drugs in the body, 849,<br />

851–852, 852<br />

alcohol, 71–72<br />

drug testing <strong>and</strong>, 450<br />

1835<br />

Disulfiram, 410–412<br />

with alcohol, 59, 60, 61, 74, 307, 436<br />

for alcoholism, 436, 463, 970, 1152, 1252<br />

behavioral economics <strong>and</strong>, 168–170<br />

clinical trial on, 1151–1152<br />

for cocaine polydrug addiction,<br />

1170–1171, 1196<br />

liver disorders <strong>and</strong>, 311<br />

Diuretics, caffeine as, 212–213<br />

Divorce <strong>and</strong> substance abuse, 516, 526<br />

DMT. See Dimethyltryptamine<br />

Doctors. See Physicians<br />

Dogol<strong>of</strong>f, Lee I.<br />

DPO <strong>and</strong>, 1280, 1285<br />

SAODAP <strong>and</strong>, 1302<br />

Dogs for drug detection, 412–414, 413<br />

Dole, Vincent, 716, 717, 818–819, 1125<br />

Dolophine. See Methadone<br />

DOM, 414, 589–590, 1024<br />

chemical structure <strong>of</strong>, 414, 590, 707<br />

Domestic Council Drug Abuse Task Force,<br />

1284<br />

Domestic violence. See Family violence<br />

Donfeld, Jeffrey, 1309<br />

Dopa<br />

conversion <strong>of</strong>, 223<br />

dopamine <strong>and</strong>, 414<br />

Dopamine, 414–415, 1154<br />

alcohol <strong>and</strong>, 233, 1154, 1252<br />

amantadine <strong>and</strong>, 106<br />

amphetamine effects on, 111, 224,<br />

225–226, 226<br />

amygdala <strong>and</strong>, 122<br />

antisocial personality disorder <strong>and</strong>, 138<br />

cocaethylene <strong>and</strong>, 267<br />

cocaine effects on, 106, 111, 224–226,<br />

226, 269, 271, 1347<br />

pharmacotherapy for, 1159, 1254<br />

prolactin <strong>and</strong>, 1168–1169<br />

conversion <strong>of</strong>, 223<br />

dynorphin <strong>and</strong>, 474<br />

euphoric properties <strong>of</strong> drugs <strong>and</strong>,<br />

193–196, 194, 195<br />

hallucinations <strong>and</strong>, 586, 589–590<br />

harmine effects on, 157<br />

intracranial self-stimulation <strong>and</strong>, 1007<br />

limbic system <strong>and</strong>, 688–689<br />

MDMA <strong>and</strong>, 707<br />

memory <strong>and</strong>, 712<br />

motivation <strong>and</strong>, 984–985<br />

neurotransmission <strong>and</strong>, 194, 777–779,<br />

780–781<br />

opioids effects on, 228–232<br />

Parkinson disease <strong>and</strong>, 746<br />

reinforcement <strong>and</strong>, 24, 465<br />

ventral tegmental area <strong>and</strong>, 1308–1309<br />

Dopaminergic agents, for cocaine<br />

withdrawal, 1170<br />

Doping Compounds Act <strong>of</strong> 1992 (Sweden),<br />

1067<br />

Doral. See Quazepam<br />

Doriden. See Glutethimide<br />

Dose-response relationship, 415–416<br />

agonist-antagonist interactions, 134–135<br />

for caffeine, 211–212, 213<br />

for coca plant use, 266<br />

drug discrimination <strong>and</strong>, 973<br />

ED50 <strong>and</strong>, 477<br />

effects <strong>of</strong>, 415<br />

LD50 <strong>and</strong>, 682<br />

log scale effects <strong>of</strong>, 415<br />

memory <strong>and</strong>, 710, 712–713<br />

for methadone, 715<br />

pharmacodynamics <strong>and</strong>, 845<br />

Dostoyevsky, Fyodor, 560<br />

Double-doctoring, 747

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!